Use of Vildagliptin in Management of Type 2 Diabetes: Effectiveness, Treatment Persistence and Safety from the 2-Year Real-Life VILDA Study

Introduction There is an increasing interest for real-life data on drug use in many countries. Reimbursement authorities more and more request observational studies to assess the conditions of use of the products but also to improve knowledge about efficacy and safety in the real world and on a long...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes therapy 2014-06, Vol.5 (1), p.207-224
Main Authors: Simon, Dominique, Detournay, Bruno, Eschwege, Evelyne, Bouée, Stephane, Bringer, Jacques, Attali, Claude, Dejager, Sylvie
Format: Article
Language:English
Subjects:
Cardiology
Clinical outcomes
Clinical trials
Diabetes
Disease management
Drug therapy
Endocrinology
Internal Medicine
Medicine
Medicine & Public Health
Original Research
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Introduction There is an increasing interest for real-life data on drug use in many countries. Reimbursement authorities more and more request observational studies to assess the conditions of use of the products but also to improve knowledge about efficacy and safety in the real world and on a longer term than in clinical trials. Aim To evaluate the effectiveness, treatment persistence and tolerability of vildagliptin in clinical practice. Methods This observational, 2-year prospective cohort study was conducted in France on request of the Health Authorities [Haute Autorite de Sante (HAS)]. Type 2 diabetic mellitus (T2DM) patients initiating vildagliptin (including the fixed combination vildagliptin-metformin) or treated for
ISSN:1869-6953
1869-6961
DOI:10.1007/s13300-014-0064-0